Don’t waste your time – keep track of how NFP affects the US dollar!
The ASIC policy prohibits us from providing services to clients in your region. Are you already registered with FBS and want to continue working in your Personal area?
Personal areaOn Saturday, the US Food and Drug Administration approved Johnson&Johnson’s vaccine for emergency use against Covid-19. According to the regulator’s plan, the government will start the distribution of nearly 4 million doses of JNJ’s vaccine across the nation as soon as this week. This is the third vaccine to be supplied to the pharmacies and community health centers of the United States after Pfizer’s and Moderna’s ones. The newly approved vaccine has some unique features, though. Firstly, it requires only one dose. Secondly, it can be stored at refrigerator temperatures for months. The overall effectiveness of Johnson&Johnson’s vaccine varies by region with 72% in the United States, 66% in Latin America, and 57% in South Africa. The numbers seem low in comparison with Moderna’s or Pfizer’s vaccines. However, experts tell that the vaccines are hard to compare, as Johnson&Johnson is a single-shot vaccine and the trial was conducted when there were more infections. At the same time, the company announced the 100% effectiveness against death and hospitalizations caused by Covid-19.
Dr. Anthony Fauci, the chief medical advisor to President Joe Biden, told Americans not to hesitate the vaccine by J&J. According to his words, “It’s not the weaker vaccine, they are all three really good vaccines.”
The news has definitely improved risk sentiment in the market. As for the JNJ stock itself, it was trading at 161.64 pre-market, rising by 2.01% from Friday’s close. Last month, the JNJ stock broke the uptrend and fell below the 160 level. Given current optimism, there is a possibility for it to restore its stronger position. The first resistance for the stock lies at 164.4. In case of the cautious risk, the stock will fall to 156.7.
